Literature DB >> 29399743

Predicted environmental concentration and fate of the top 10 most dispensed Australian prescription pharmaceuticals.

Timothy T X Ong1, Ewan W Blanch2, Oliver A H Jones3.   

Abstract

A basic environmental risk assessment was carried out for the top 10 dispensed pharmaceuticals in Melbourne, Australia, in contrast to the more commonly assessed measure of the most used drugs by physical mass. This allowed for the evaluation of compounds that had not previously been the subject of risk assessment. Estimations of the possible fate and behaviour of the target pharmaceuticals in sewage treatment plants were also made. The predicted removal rates of most drugs within standard sewage treatment were expected to be low, with the exception of the statins, which had high removal rates. Each pharmaceutical was predicted to be present in Melbourne wastewater at the nanogram per litre range or lower. All compounds were predicted to be of low toxicity risk, although it was not possible to model mixture effects. Atorvastatin and Irbesartan were also found to possess the potential to possibly bioaccumulate in the aquatic food chain but not to the extent that would require regulation or labelling.

Entities:  

Keywords:  Australia; EPI Suite; Environmental fate; Medicines; Modelling; Risk assessment; Wastewater

Mesh:

Substances:

Year:  2018        PMID: 29399743     DOI: 10.1007/s11356-018-1343-5

Source DB:  PubMed          Journal:  Environ Sci Pollut Res Int        ISSN: 0944-1344            Impact factor:   4.223


  37 in total

1.  Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use.

Authors:  F Stuer-Lauridsen; M Birkved; L P Hansen; H C Lützhøft; B Halling-Sørensen
Journal:  Chemosphere       Date:  2000-04       Impact factor: 7.086

2.  Methodological approaches for studying pharmaceuticals in the environment by comparing predicted and measured concentrations in River Po, Italy.

Authors:  Sara Castiglioni; Roberto Fanelli; Davide Calamari; Renzo Bagnati; Ettore Zuccato
Journal:  Regul Toxicol Pharmacol       Date:  2004-02       Impact factor: 3.271

3.  Occurrence of pharmaceutically active and non-steroidal estrogenic compounds in three different wastewater recycling schemes in Australia.

Authors:  Jawad H Al-Rifai; Candace L Gabelish; Andrea I Schäfer
Journal:  Chemosphere       Date:  2007-06-20       Impact factor: 7.086

4.  Oxidative removal of selected endocrine-disruptors and pharmaceuticals in drinking water treatment systems, and identification of degradation products of triclosan.

Authors:  Qihua Wu; Honglan Shi; Craig D Adams; Terry Timmons; Yinfa Ma
Journal:  Sci Total Environ       Date:  2012-10-09       Impact factor: 7.963

5.  Metabolism and kinetics of amlodipine in man.

Authors:  A P Beresford; D McGibney; M J Humphrey; P V Macrae; D A Stopher
Journal:  Xenobiotica       Date:  1988-02       Impact factor: 1.908

6.  Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.

Authors:  M Pfister; F Schaedeli; F J Frey; D E Uehlinger
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

7.  Sorption and degradation of selected five endocrine disrupting chemicals in aquifer material.

Authors:  Guang-Guo Ying; Rai S Kookana; Peter Dillon
Journal:  Water Res       Date:  2003-09       Impact factor: 11.236

8.  Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man.

Authors:  M Verho; C Luck; W J Stelter; B Rangoonwala; N Bender
Journal:  Curr Med Res Opin       Date:  1995       Impact factor: 2.580

9.  Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.

Authors:  Paul D Martin; Mike J Warwick; Aaron L Dane; Steve J Hill; Petrina B Giles; Paul J Phillips; Eva Lenz
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

Review 10.  Pharmaceuticals and personal care products in the environment: agents of subtle change?

Authors:  C G Daughton; T A Ternes
Journal:  Environ Health Perspect       Date:  1999-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.